BackgroundGlioblastoma (GBM) is the most common malignant primary brain tumor. Emerging reports have suggested that racial and socioeconomic disparities influence the outcomes of patients with GBM. No studies to date have investigated these disparities controlling for isocitrate dehydrogenase (IDH) mutation and O‐6‐methylguanine‐DNA methyltransferase (MGMT) status.MethodsAdult patients with GBM were retrospectively reviewed at a single institution from 2008 to 2019. Univariable and multivariable complete survival analyses were performed. A Cox proportional hazards model was used to assess the effect of race and socioeconomic status controlling for a priori selected variables with known relevance to survival.ResultsIn total, 995 patients met inclusion criteria. Of these, 117 patients (11.7%) were African American (AA). The median overall survival for the entire cohort was 14.23 months. In the multivariable model, AA patients had better survival compared with White patients (hazard ratio [HR], 0.37; 95% confidence interval [CI], 0.2–0.69). The observed survival difference was significant in both a complete case analysis model and a multiple imputations model accounting for missing molecular data and controlling for treatment and socioeconomic status. AA patients with low income (HR, 2.17; 95% CI, 1.04–4.50), public insurance (HR, 2.25; 95% CI, 1.04–4.87), or no insurance (HR, 15.63; 95% CI, 2.72–89.67) had worse survival compared with White patients with low income, public insurance, or no insurance, respectively.ConclusionsSignificant racial and socioeconomic disparities were identified after controlling for treatment, GBM genetic profile, and other variables associated with survival. Overall, AA patients demonstrated better survival. These findings may suggest the possibility of a protective genetic advantage in AA patients.Plain Language Summary
To best personalize treatment for and understand the causes of glioblastoma, racial and socioeconomic influences must be examined.
The authors report their experience at the O’Neal Comprehensive Cancer Center in the deep south.
In this report, contemporary molecular diagnostic data are included.
The authors conclude that there are significant racial and socioeconomic disparities that influence glioblastoma outcome and that African American patients do better.